R&D News | pharmaphorum

News

AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.

News

Matchpoint has closed a $150m round for its immunology-focused covalent drugs, with KymaThera, Rouge, Sensible Bio, and Arboretum also raising funds.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

News

The Nobel Prize in Chemistry 2026 has been awarded to Henri B Kagan and Kensō Soai for their discoveries in asymmetric organic synthesis.

News

Just months after launching an open-source 'virtual biology' platform, Biohub has raised $1.8 billion in backing for the AI-powered initiative.

News

Senior figures in European biopharma think dealmaking and M&A will increase in the region, and could be helped by US policy uncertainties.